They may have been five years in the making but the highly anticipated results for the TAME Trial arrived with a bang at this year’s Critical Care Review’s Meeting in Belfast.
Principal Investigator Glenn Eastwood and Ireland TAME Study Lead Alistair Nichol, took to the stage to announce that a strategy targeting mild hypercapnia for 24 hours did not improve neurologic outcomes at 6 months compared with targeted normocapnia.
Spiral has been on board with the TAME trial for over five years now and as one of the original trials in Spiral’s manifest we have been keenly awaiting these outcomes.
Read more on our blog